Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity PAR-23-102 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 13, 2023 Category: Research Source Type: funding

Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-097 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and p...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 6, 2023 Category: Research Source Type: funding

Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity PAR-22-035 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2021 Category: Research Source Type: funding

Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity PAR-22-036 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2021 Category: Research Source Type: funding

Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-106 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding

Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-105 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding

Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required)
Funding Opportunity RFA-MH-18-703 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic crit...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 14, 2017 Category: Research Source Type: funding

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required)
Funding Opportunity RFA-MH-18-702 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic cri...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 14, 2017 Category: Research Source Type: funding

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)
Funding Opportunity ID: 290627 Opportunity Number: RFA-MH-17-602 Opportunity Title: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.242Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Fe...
Source: Grants.gov - December 13, 2016 Category: Research Tags: Health Source Type: funding

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33)
Funding Opportunity ID: 290644 Opportunity Number: RFA-MH-17-600 Opportunity Title: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.242Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments...
Source: Grants.gov - December 13, 2016 Category: Research Tags: Health Source Type: funding

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)
Funding Opportunity RFA-MH-17-602 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 13, 2016 Category: Research Source Type: funding

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33)
Funding Opportunity RFA-MH-17-600 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnosti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 13, 2016 Category: Research Source Type: funding

Request for Information (RFI) DE-FOA-0001510: Research, Development and Business Strategies Needs for Hydrogen and Automotive Polymer Electrolyte Membrane (PEM) Fuel Cells
Funding Opportunity Number: DE-FOA-0001510 Opportunity Category: DiscretionaryFunding Instrument Type: OtherCategory of Funding Activity: EnergyCFDA Number: 81.087Eligible Applicants Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Agency Name: DOE-GFOClosing Date: Mar 25, 2016Award Ceiling: $100Expected Number of Awards: 0Creation Date: Mar 04, 2016Funding Opportunity Description: The Fuel Cell Technologies Office (FCTO) is seeking feedback from the research community, relevant stakeho...
Source: Grants.gov - March 5, 2016 Category: Research Tags: Energy Source Type: funding

Alexander Gralnick Research Investigator Prize
$20,000 to support exceptional research and mentoring accomplishments in the area of serious mental illness. Deadline: April 15, 2016 Sponsor: American Psychological Foundation The $20,000 grant supports “exceptional individuals working in the area of serious mental illness,” including but not limited to schizophrenia, bipolar disorder and paranoia (delusional disorder). The American Psychological Foundation provides financial support for innovative research and programs that enhance the power of psychology to elevate the human condition and advance human potential both now and in generatio...
Source: ScanGrants feed - November 14, 2014 Category: Research Authors: American Psychological Foundation Source Type: funding

Samuel Gershon Junior Investigator Awards
Deadline: 22 September 2014 In an ongoing effort to recognize the outstanding work of future leaders in the field, the International Society for Bipolar Disorders (ISBD), will again offer the Samuel Gershon Junior Investigator Awards to up to four young investigators for their original research publication submissions.  The Award is named in honor of Dr. Samuel Gershon, an early pioneer of lithium research who brought lithium from Australia to the United States. He was a founding member of the ISBD, the first elected president of the organization, and is Co-Editor of Bipolar Disorders: An International Journa...
Source: ScanGrants feed - August 5, 2014 Category: Research Authors: International Society for Bipolar Disorders Source Type: funding